What is the address of BIOPATH.MED?

The registered office of BIOPATH.MED is located at Rue Neuve(F) 21, 1350 Orp-Jauche.

Is BIOPATH.MED still active?

Yes. According to the CBE (29 October 2026) BIOPATH.MED is active, legal situation “Normale toestand”, started on 23 December 2013.

Is BIOPATH.MED registered on Peppol?

Yes, BIOPATH.MED is registered on the Peppol network with ID 0208:0543629372.

What is the enterprise number of BIOPATH.MED?

The enterprise number of BIOPATH.MED is BE0543629372.

When was BIOPATH.MED founded?

BIOPATH.MED was founded on 23 December 2013.

Who are the directors of BIOPATH.MED?

According to the 2025 annual accounts, the directors of BIOPATH.MED are: Jacques Mairesse, Valérie Selosse.

Is BIOPATH.MED a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 23 December 2013; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did BIOPATH.MED make in 2025?

BIOPATH.MED recorded a loss after taxes of € 10,505 in financial year 2025.

What is the revenue of BIOPATH.MED?

As a small company, BIOPATH.MED is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -17,822.

BIOPATH.MED (Private Limited) - Orp-Jauche - BE0543629372

Dossier BIOPATH.MED, printed on 29 October 2026 from databakkes.be/en/0543629372/biopath-med. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

BIOPATH.MED from Orp-Jauche, company number BE0543629372, closed financial year 2025 with a result of € -10,505 after tax. For that financial year BIOPATH.MED recorded a gross margin of € -17,822 and equity of € 561,200. Compared with financial year 2024, the result moved from € 5,719 to € -10,505. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 17, 2026.

What it is worth Healthy

€ 561,200

▼ 3% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -10,505

▼ still € 5,719 profit in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 110,378

▲ 117% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 542,600.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 5,479

▲ 63% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 1,636

▲ 28% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -3,730 Gross margin 2022: € -3,730 First fiscal year in the series	€ -22,427 Gross margin 2023: € -22,427 ▼ € 18,697 vs 2022 (€ -3,730) Unfavourable step	€ -14,862 Gross margin 2024: € -14,862 ▲ € 7,565 vs 2023 (€ -22,427) Favourable step	€ -17,822 Gross margin 2025: € -17,822 ▼ € 2,960 vs 2024 (€ -14,862) Unfavourable step	▼ € 2,960
Profit after taxes	€ -13,058 Profit after taxes 2022: € -13,058 First fiscal year in the series	€ -11,938 Profit after taxes 2023: € -11,938 ▲ € 1,120 vs 2022 (€ -13,058) Favourable step	€ 5,719 Profit after taxes 2024: € 5,719 ▲ € 17,657 vs 2023 (€ -11,938) Favourable step	€ -10,505 Profit after taxes 2025: € -10,505 ▼ € 16,224 vs 2024 (€ 5,719) Unfavourable step	▼ € 16,224
Equity	€ 658,048 Equity 2022: € 658,048 First fiscal year in the series	€ 608,215 Equity 2023: € 608,215 ▼ 8% vs 2022 (€ 658,048) Unfavourable step	€ 578,934 Equity 2024: € 578,934 ▼ 5% vs 2023 (€ 608,215) Unfavourable step	€ 561,200 Equity 2025: € 561,200 ▼ 3% vs 2024 (€ 578,934) Unfavourable step	▼ 3%
Total debts	€ 10,494 Total debts 2022: € 10,494 First fiscal year in the series	€ 40,176 Total debts 2023: € 40,176 ▲ 283% vs 2022 (€ 10,494) Unfavourable step	€ 38,543 Total debts 2024: € 38,543 ▼ 4% vs 2023 (€ 40,176) Favourable step	€ 8,174 Total debts 2025: € 8,174 ▼ 79% vs 2024 (€ 38,543) Favourable step	▼ 79%
Cash	€ 655,614 Cash 2022: € 655,614 First fiscal year in the series	€ 99,906 Cash 2023: € 99,906 ▼ 85% vs 2022 (€ 655,614) Unfavourable step	€ 50,957 Cash 2024: € 50,957 ▼ 49% vs 2023 (€ 99,906) Unfavourable step	€ 110,378 Cash 2025: € 110,378 ▲ 117% vs 2024 (€ 50,957) Favourable step	▲ 117%
Retained profit	€ 639,448 Retained profit 2022: € 639,448 First fiscal year in the series	€ 589,615 Retained profit 2023: € 589,615 ▼ 8% vs 2022 (€ 639,448) Unfavourable step	€ 560,334 Retained profit 2024: € 560,334 ▼ 5% vs 2023 (€ 589,615) Unfavourable step	€ 542,600 Retained profit 2025: € 542,600 ▼ 3% vs 2024 (€ 560,334) Unfavourable step	▼ 3%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 37,895 Dividend 2023: € 37,895 Unchanged (€ 0) Unchanged	€ 35,000 Dividend 2024: € 35,000 ▼ 8% vs 2023 (€ 37,895) Unchanged	€ 7,228 Dividend 2025: € 7,228 ▼ 79% vs 2024 (€ 35,000) Unchanged	▼ 79%
Balance sheet total	€ 668,542 Balance sheet total 2022: € 668,542 First fiscal year in the series	€ 648,391 Balance sheet total 2023: € 648,391 ▼ 3% vs 2022 (€ 668,542) Unchanged	€ 617,477 Balance sheet total 2024: € 617,477 ▼ 5% vs 2023 (€ 648,391) Unchanged	€ 569,374 Balance sheet total 2025: € 569,374 ▼ 8% vs 2024 (€ 617,477) Unchanged	▼ 8%

Key figures of BIOPATH.MED, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to BIOPATH.MED?

What happened at BIOPATH.MED in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 17, 2026 New annual accounts for financial year 2025: loss of € 10,505 (▼ € 16,224 vs 2024). Source: NBB ↗
Jan 1, 2014 New establishment in Orp-Jauche. KBO
2013 Jacques Mairesse became a director. NBB
2013 Valérie Selosse became a director. NBB
Dec 23, 2013 Start of the company according to the CBE. KBO

In short

From € 13,058 loss in 2022 to € 10,505 loss in 2025.

Paid € 6,525 in corporate taxes since 2022.

Best year ever: 2024, with € 5,719 profit.

Paid out € 80,123 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Jacques Mairesse Valérie Selosse

BIOPATH.MED

ETABLISSEMENT LA TRANSFUSION DU SANG

Behind BIOPATH.MED are Jacques Mairesse and Valérie Selosse. Valérie Selosse is also behind ETABLISSEMENT LA TRANSFUSION DU SANG.

Directors

According to the 2025 annual accounts

Jacques Mairesse

Director

since 2013

Valérie Selosse

Director

Also active at: ETABLISSEMENT LA TRANSFUSION DU SANG

since 2013

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Neuve(F) 21

1350 Orp-Jauche

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0543.629.372
VAT number: BE 0543.629.372
Registered office: Rue Neuve(F) 21, 1350 Orp-Jauche
Names & denominations: BIOPATH.MED
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 23 December 2013
Peppol: Active · Active since 20 Nov 2020

View on CBE Public ↗ Annual accounts (NBB) ↗